Teramo (Italy) and Charlotte, N.C. (USA), on April 3, 2023 – Azienda Farmaceutica Italiana (“AFI”), an Italian pharmaceutical company and innovator in therapeutic solutions and new treatment possibilities, and TannerLAC, Inc. (“TannerLAC”), a division of Tanner Pharma Group, have entered into a license agreement for the distribution of Hepilor® in Latin America.
Hepilor® is a medical device, indicated for the protection of the digestive system mucosa. Hepilor® adheres to the damaged, ulcerated and inflamed mucosa and works as a mucosal defense agent to protect and promote natural healing of the gastrointestinal mucosal lining and relieve dyspeptic symptoms. This line of products is available in both liquid (200 ml) and capsule (20 capsules of 37.5mg) formats, as well as mouthwash (150ml) and as a single-dose stick-pack.
TannerLAC provides pharmaceutical, biotech and healthcare companies with a single-point partner for the commercialization of their products in challenging international markets. AFI, through the support of their partner PB Pharma Group, engaged TannerLAC to bring this mucosal defense agent to gastric patients in Latin America. Under the license agreement, TannerLAC will be responsible for the registration, commercialization and promotion of Hepilor® in Latin American countries. The official launch of the product in this region, including Mexico and most countries throughout Central and South America, is expected for 2024.
Carolina Cortez, EVP of TannerLAC, commented “Given the increasing number of patients developing gastrointestinal disorders worldwide, we were very pleased when we were introduced to Hepilor® by PB Pharma Group. This product has different formulations that act directly on digestive system mucosa and can treat a variety of diseases. We have heard touching testimonies of patients who have been positively impacted with the use of the product. Therefore, we are eager to work with AFI’s innovative team to bring Hepilor® to Latin America and help many patients in need.”
Miro Costantini and Lorenzo Monticelli, Owners & CEO’s of AFI, commented “It has been always our dream to develop innovative and breakthrough products, sharing our experience in the research & developing with a partner with huge knowledge and amazing experience in international markets. With Tanner we have found not only this but something more, a wonderful and extremely professional team. It will be exciting to work with them sharing the same goals.”
About Tanner Pharma Group
Tanner Pharma Group is a specialist pharmaceutical partner focused on improving global access to medicines. By partnering with Tanner Pharma, companies can focus on their primary markets while ensuring that patients and clinicians in international markets can also benefit from using their products. Tanner Pharma has a global reach and provides international commercialization and patient access through product registration and licensing, managed and global access programs and clinical trial solutions. For more information, please visit www.tannerpharma.com.